Physician profile
Patrick E Mcmanus
NPI 1932180247
$6,258.64
in general payments reported to CMS, 2019-2025
31 companies · $688 in 2025
The $688 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $924 · 2021: $761 · 2022: $1,346 · 2023: $706 · 2024: $950 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $86.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.40 |
| Education | $86.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,136.68 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $895.78 | 2021-2022 | |
| Abbvie INC. | $833.62 | 2019-2025 | |
| Exeltis, USA INC. | $690.74 | 2019-2025 | Slynd |
| Millicent US INC | $490.58 | 2019-2025 | Intrarosa, Femlyv |
| Evofem Biosciences, INC. | $266.38 | 2021-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $214.50 | 2019-2020 | |
| Pfizer INC. | $211.14 | 2019-2023 | |
| Therapeuticsmd, INC. | $196.49 | 2019-2022 | |
| Organon LLC | $189.45 | 2021-2024 | Nexplanon |
| Avion Pharmaceuticals | $183.54 | 2019-2022 | |
| Lupin INC. | $159.61 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $141.39 | 2023-2024 | Ztlido, Elyxyb |
| Scynexis, INC. | $105.27 | 2022 | |
| Mayne Pharma Commercial LLC | $62.59 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $62.31 | 2021-2023 | Twirla |
| Merck Sharp & Dohme LLC | $57.69 | 2020-2021 | |
| Biogen, INC. | $54.07 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $52.28 | 2019 | |
| Amag Pharmaceuticals, INC. | $43.08 | 2019 | |
| Mission Pharmacal Company | $37.10 | 2021-2022 | |
| Exact Sciences Corporation | $26.49 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $21.81 | 2019 | |
| Coopersurgical, INC. | $21.59 | 2022 | |
| Karl Storz Endoscopy-America | $19.11 | 2019 | |
| Glaxosmithkline, LLC. | $16.38 | 2023 | Arexvy, Shingrix |
| Shield Therapeutics INC | $16.11 | 2025 | |
| Roche Diagnostics Corporation | $14.04 | 2019 | |
| Hologic Sales and Service, LLC | $13.58 | 2019 | |
| Meditrina | $12.69 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.